Today’s Silver Reporter Kim In-han | 2023.03.21 13:19
Korea Brain Research Institute confirms improvement in Alzheimer’s disease with breast cancer treatment ‘Abemaciclib’
A Korean research team has discovered that the breast cancer drug ‘abemaciclime mesylate’ is also effective in treating Alzheimer’s disease. This treatment is a targeted anti-cancer drug that stops the spread of breast cancer cells by regulating the cell cycle, and this is the first time it has been found to even be effective in treating breast cancer. brain.
According to the Korea Brain Research Institute on the 21st, the research team led by Ph. It involves identifying the mechanism by which breast cancer treatment improves Alzheimer’s disease through animal experiments.
Alzheimer’s is a degenerative brain disease commonly known as dementia. In the early stage of the disease, the person cannot remember recent events, and then together with other cognitive function abnormalities such as language function and judgment, and eventually everyday life becomes impossible. Due to the complex structure of the brain, the cause and principle of action of the drug cannot be identified.
The research team said they started the study after seeing data from abroad that patients who take breast cancer treatment are less prone to Alzheimer’s disease. So far, studies have only concluded that breast cancer treatments are effective for Alzheimer’s disease, but the scientific reason and clear mechanism have not been identified.
The research team created an animal model suffering from Alzheimer’s disease and gave it abemaciclib. As a result, it was confirmed that the formation of dendrites in nerve cells was promoted, and short-term memory and recognition memory were restored. In particular, by regulating the expression of ‘DYRK1A’ and ‘p-GSK3β’ genes, it reduced the protein amyloid plaques that cause Alzheimer’s disease and prevented other tau protein lesions.
Dr. Heo Hyang-sook said, “The brains of Alzheimer’s patients overexpress the CDK4 gene than normal people, but we found that abemaciclib controls CDK4/6 to have a medicinal effect on Alzheimer’s. “We plan to start a clinical study.” The research team intend to carry out follow-up research based on related research and implement it in practice.
[저작권자 @머니투데이, 무단전재 및 재배포 금지]